No reflow phenomenon

No-reflow phenomenon
Synonyms
Pronounce	N/A
Specialty	N/A
Symptoms	Impaired blood flow despite open coronary artery
Complications	Myocardial infarction, heart failure
Onset	During or after percutaneous coronary intervention
Duration	Variable
Types	N/A
Causes	Microvascular obstruction, endothelial dysfunction
Risks	Diabetes mellitus, hypertension, hyperlipidemia
Diagnosis	Coronary angiography, cardiac MRI
Differential diagnosis	Coronary artery spasm, thrombus
Prevention	Adequate antiplatelet therapy, statins
Treatment	Vasodilators, antioxidants, anti-inflammatory drugs
Medication	N/A
Prognosis	Variable, depends on extent of microvascular damage
Frequency	Occurs in 2-5% of percutaneous coronary intervention cases
Deaths	N/A

No Reflow Phenomenon

The no reflow phenomenon is a medical condition that occurs when there is an inadequate blood flow to a region of the heart muscle after the reopening of a blocked coronary artery. This phenomenon is often observed after procedures such as percutaneous coronary intervention (PCI) or thrombolysis in patients with acute myocardial infarction.

Pathophysiology

The no reflow phenomenon is characterized by the inability of blood to adequately perfuse the microvasculature despite the successful removal of a blockage in a larger vessel. This can be due to several factors, including microvascular damage, endothelial dysfunction, and the presence of microemboli. The condition can lead to further myocardial damage and is associated with worse clinical outcomes.

Causes

Several mechanisms have been proposed to explain the no reflow phenomenon:

• Microvascular obstruction: This occurs when small blood vessels are blocked by debris or thrombi that have broken off from the main blockage.
• Endothelial injury: Damage to the endothelial cells lining the blood vessels can lead to impaired vasodilation and increased vascular resistance.
• Inflammation: Inflammatory processes can exacerbate microvascular dysfunction and contribute to no reflow.
• Reperfusion injury: The restoration of blood flow can itself cause damage to the microvasculature, leading to no reflow.

Clinical Implications

The presence of the no reflow phenomenon is associated with a higher risk of adverse outcomes, including increased mortality, larger infarct size, and reduced left ventricular function. It is important for clinicians to recognize and address this condition to improve patient outcomes.

Management

Management strategies for the no reflow phenomenon include pharmacological and mechanical interventions:

• Pharmacological therapy: Medications such as adenosine, calcium channel blockers, and nitroglycerin can be used to improve microvascular flow.
• Mechanical interventions: Techniques such as thrombectomy or the use of specialized devices to remove microemboli may be employed.

Related Pages

• Myocardial infarction
• Coronary artery disease
• Percutaneous coronary intervention
• Reperfusion injury

Cardiovascular disease A-Z

Most common cardiac diseases

• Cardiac arrhythmia‎
• Cardiogenetic disorders‎
• Cardiomegaly‎
• Cardiomyopathy‎
• Cardiopulmonary resuscitation‎
• Chronic rheumatic heart diseases‎
• Congenital heart defects‎
• Heart neoplasia‎
• Ischemic heart diseases‎
• Pericardial disorders
• Syndromes affecting the heart‎
• Valvular heart disease‎

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A

• Accelerated idioventricular rhythm
• Acute decompensated heart failure
• Arteriosclerotic heart disease
• Athletic heart syndrome
• Atrial flutter
• Atrioventricular fistula
• Cardiovascular disease in Australia
• Autoimmune heart disease

B

• Brown atrophy of the heart

C

• Ebb Cade
• Cardiac allograft vasculopathy
• Cardiac amyloidosis
• Cardiac asthma
• Cardiac tamponade
• Cardiogenic shock
• Cardiogeriatrics
• Cardiorenal syndrome
• Cardiotoxicity
• Carditis
• Coronary artery aneurysm
• Coronary artery anomaly
• Coronary artery disease
• Spontaneous coronary artery dissection
• Coronary artery ectasia
• Coronary occlusion
• Coronary steal
• Coronary thrombosis
• Coronary vasospasm
• Cœur en sabot
• Coxsackievirus-induced cardiomyopathy

D

• Duke Treadmill Score
• Duroziez's disease

E

• Eisenmenger's syndrome
• Embryocardia
• Endocardial fibroelastosis
• Eosinophilic myocarditis

H

• Heart attack
• Heart failure
• Heart failure with preserved ejection fraction
• Heart to Heart (1949 film)
• High-output heart failure
• Hyperdynamic precordium

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I

• Idiopathic giant-cell myocarditis
• Interventricular dyssynchrony
• Intraventricular dyssynchrony
• Isolated atrial amyloidosis

K

• Keshan disease

L

• Loeffler endocarditis

M

• Mydicar
• Myocardial bridge
• Myocardial disarray
• Myocardial rupture
• Myocardial scarring
• Myocardial stunning
• Myocarditis

N

• Nonbacterial thrombotic endocarditis

O

• OLR1
• Ostial disease

P

• Papillary fibroelastoma
• Pathophysiology of heart failure
• Postpericardiotomy syndrome
• Pulmonary vein stenosis

R

• Right axis deviation
• Roemheld syndrome

S

• Saturated fat and cardiovascular disease
• SCAR-Fc
• Shone's syndrome
• Strain pattern
• Subacute bacterial endocarditis
• Sudden cardiac death of athletes

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

T

• Traumatic cardiac arrest

V

• Ventricular aneurysm
• Vibroacoustic disease
• Viral cardiomyopathy

W

• Waon therapy